News

Hot deal to cool immune response
Enlarge image

BusinessFrance

Hot deal to cool immune response

30.11.2012 - Selecta Biosciences and Sanofi have signed a global collaboration to develop antigen-specific immunotherapies for up to three allergy indications.

The US-based biotech has developed a synthetic vaccine particle technology which is now being licensed to the French pharma for up to US$900m including a number of milestone payments. The agreement gives Sanofi the right to develop a therapy to fight an immune response triggered by a life-threatening food allergen. Furthermore, Sanofi may develop two other compounds. The pharma got in touch following the lure of the technology discovered in the lab of Bob Langer at the MIT.

Selecta engineers nanoparticles with the structure required to stimulate immune tolerance thereby controlling overactive response to antigens. Selecta won substantial backing from RusNano last autumn, agreeing to set up operations in Russia as part of the deal. Privately held Selecta is a shooting star since its foundation in 2008, raising more than US-$32m in three venture rounds, finally attracting the attention of Rusnano. Last year, the US$10bn Russian fund joined Selecta’s existing investor base. The consortium spent US$47.25m to broaden the company’s R&D capabilities and accelerate its pipeline of vaccines and immunotherapies.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/hot-deal-to-cool-immune-response.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTECH PHARMACON (N)16.80 NOK17.07%
  • ALMIRALL (E)17.26 EUR4.61%
  • EUROFINS SCIENTIFIC (F)301.96 EUR4.16%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • DBV TECHNOLOGIES (F)67.75 EUR-7.57%
  • CO.DON (D)2.50 EUR-7.41%

TOP

  • KARO BIO (S)39.30 SEK2371.7%
  • BIOTECH PHARMACON (N)16.80 NOK77.8%
  • TRANSGENE (F)4.92 EUR71.4%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.86 EUR-43.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-41.2%

TOP

  • KARO BIO (S)39.30 SEK4692.7%
  • ADOCIA (F)82.29 EUR384.9%
  • VERONA PHARMA (UK)5.00 GBP316.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • EVOCUTIS (UK)0.18 GBP-81.2%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-80.1%

No liability assumed, Date: 01.09.2015